Financials
- Financial year
- 2025
- Total assets
- €18.5m
- Profit
- €2.8m
- Solvency
- 61.4%
Total assets▲ 73.9%
Net result
20192025
Alixar
ActiveSummary
Alixar has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €11.3m and a net result of €2.8m. Equity is growing by about 79% per year across the filed financial years. Its solvency ranks better than 51% of 613 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Activity
Research and development on biotechnology
NACE 72101
2nd largest company by equity in Limburg, Research and development sector1 site
Size
€18.5mtotal assets 2025
- Equity
- €11.3m
- Profit
- €2.8m
Turnover not published (micro format)
Structure
2025 accounts 10 days early1 of 3 deeds summarised
Why 97raises riskLiquidity: current ratio 23.26, cash €98,374, halvedlowers riskSize: total assets €18.5mFigures for financial year 2025 (filed 21-07-2026)Sector: Scientific research and development (NACE 72)Show the evidence
Checked score
Score 2025
97
/ 100
Excellent
Probability in this band: under 0.55%
Financially better than 79% of its sector peers (NACE 72, medium-sized)
Financial strength · tick = 2024
Strong
Solvency
86-14
equity 61.4% of total assets
Liquidity
51-2
short-term debt 4.3% · cash 0.5%
Profitability
88+13
return on assets 15.4%
Bankruptcy probability, 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.1%
12-2024: 0.1%● unchanged vs 11-2024
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.2%▲ +0.1 percentage points vs 03-2025
05-2025: 0.2%● unchanged vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025
07-2025: 0.3%▲ +0.1 percentage points vs 06-2025highest value
08-2025: 0.1%▼ -0.2 percentage points vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.2%▲ +0.1 percentage points vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.3%▲ +0.1 percentage points vs 06-2026
08-2026: 0.2%▼ -0.1 percentage points vs 07-2026
09-2026: 0.2%● unchanged vs 08-2026
10-2026: 0.1%▼ -0.1 percentage points vs 09-2026lowest value
Credit of up to €1,050,000 on 30-day terms is acceptable
Liquidity ample (current ratio 23.26, compared with 8.91 in 2024, above the usual 1.5; short-term debt: 4.3% and cash: 0.5% of total assets), and 38.6% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, medium-sized): better than 66% on solvency, 60% on liquidity, 94% on profitability and 96% on growth.
The bankruptcy probability was computed on 25-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 21-07-2026, 10 days ahead of the deadline.
NBB · 7 filingsDeviation from the deadline
2025
10 days early
2024
2 days early
2023
18 days early
2022
5 days early
2021
3 days early
2020
4 days early
2019
34 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 1 day before the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 26 July (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
25-10-2026 today31-12-2026 year end31-07-2027 deadline
- Annual accounts filedfinancial year 2025 · micro…
- Liquidity more than doubledcurrent ratio 23.26
- Equity above €10mequity €11.3m ▲30.4%
Key points
- Positive: Result rose in 2025from €509,159 to €2.8m ▲ 457% View
- Positive: Among the best 5% on net resultsector median €26,700 · 613 companies €2.8m View
- Positive: 7 profitable years in a rowprofit 2025: €2.8m 7 years View
- Positive: Filed on time since financial year 2020accounts within the deadline every year 6 years View
By topic
Timeline
- Events
- 17
- Since
- 2020
- Next accounts
- by 31-07-2027
- 29-07-2025Annual accounts filed
- 31-12-2024Liquidity more than doubled
- 09-10-2024Registered office
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Research and development on biotechnologyNACE 72101
- Founded
- 05-04-2018
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Key facts about Alixar
- What is the company number of Alixar?
- 0693.937.307. In Belgium the VAT number is the company number with BE in front: BE 0693.937.307.
- Where is Alixar based?
- The registered office is at Waterstraat 5, 3511 Hasselt.Company details
- What does Alixar do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of Alixar?
- Private limited company (BV).
- When was Alixar founded?
- On 05-04-2018.
- Is Alixar still active?
- Yes, Alixar is an active enterprise in the KBO register.
- What is the turnover of Alixar?
- Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.Financials
- Is Alixar profitable?
- In financial year 2025, Alixar made a profit of €2.8m.
- Where can I find the annual accounts of Alixar?
- Alixar filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Alixar due?
- By 31-07-2027, for financial year 2026.Timeline
Companies related to Alixar
Comparable companies
- Aphea.BioGent
- AstriVax TherapeuticsLeuven
- de Duve InstituteSint-Lambrechts-Woluwe
- SHANT BIOTECHTubize
- BELGIAN VOLITIONGembloux
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.